Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealings

17 Jan 2017 15:30

RNS Number : 3933U
Diurnal Group PLC
17 January 2017
 

17 January 2017

 

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealings

 

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, received notification of the following purchase of shares by a person closely associated to a Company Director on 16 January 2017:

 

Mrs Lynne Raymond, wife of Alan Raymond, Non-executive Director, purchased 9,000 ordinary shares of 5.0 pence each in the Company ("Ordinary Shares") at a price of 110 pence per Ordinary Share. Following the transaction, Alan Raymond and his connected parties have a total interest of 22,888 Ordinary Shares, representing 0.04% of the total voting rights.

 

 

 

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, CEO

Richard Bungay, CFO

Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam

Corporate Broking: James Black

FTI Consulting

+44 (0)20 3727 1000

Simon Conway

Victoria Foster Mitchell

 

Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk 

 

 

DEALING NOTIFICATION FORM FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Lynne Ryamond

Reason for the notification

a)

Position/status:

Closely associated person to a Non-Executive Director

b)

Initial notification/Amendment:

Initial

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Diurnal Group plc

b)

LEI:

n/a

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

 

Identification code:

Ordinary shares of 5p each.

 

 

GB00BDB6Q760

b)

Nature of the transaction:

Purchase

c)

Price(s) and volume(s):

Price(s)

Volume(s)

 

110p

9,000

 

d)

Aggregated information:

Aggregated volume: 9,000

 

Price: £9,900.00

e)

Date of the transaction:

16 January 2017

f)

Place of the transaction:

XLON

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFFELTIDLID
Date   Source Headline
9th Jan 20187:00 amRNSPositive results from Alkindi food matrix study
9th Jan 20187:00 amRNSBusiness Update and Notice of Interim Results
5th Jan 20185:06 pmRNSIssue of Equity
5th Jan 20185:04 pmRNSReplacement - Director Dealings
5th Jan 20181:19 pmRNSDirector Dealings
19th Dec 201712:53 pmRNSHardman Research: Alkindi®: On route to Europe
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
15th Dec 201712:11 pmRNSCHMP positive opinion for Alkindi® (Infacort®)
8th Dec 201711:30 amRNSTotal Voting Rights
29th Nov 201712:20 pmRNSDirector/PDMR Shareholding
21st Nov 201712:00 pmRNSResult of AGM
9th Nov 20176:19 pmRNSDirector Dealing and Issue of Equity
8th Nov 201712:00 pmRNSDirector/PDMR Shareholding
13th Oct 20179:00 amRNSPosting of Annual Report and AGM Notice
15th Sep 20177:00 amRNSInfacort® data published in Clinical Endocrinology
14th Sep 20177:15 amRNSHardman Research: Ready to press the button
7th Sep 20172:51 pmRNSDirector Dealings
6th Sep 20177:00 amRNSGrant of first US patent for Chronocort®
6th Sep 20177:00 amRNSResults for the year ended 30 June 2017
14th Aug 201710:00 amRNSNotice of Final Results
15th Jun 20177:00 amRNSFirst Patient Dosed in US Infacort Clinical Trial
18th May 20177:00 amRNSGrant of first US patent for Infacort
8th May 201710:03 amRNSDirector/PDMR Shareholding
27th Mar 20177:15 amRNSHardman Research:Commercial and development update
20th Mar 20177:00 amRNSInterim Results for the 6 Months Ended 31 Dec 2016
16th Mar 20177:00 amRNSLaunch of a European Patient Access programme
2nd Mar 20177:00 amRNSMarketing and Distribution Agreement
1st Mar 20177:00 amRNSNotice of Interim Results
20th Feb 20177:00 amRNSAppointment of Joint Broker
25th Jan 20177:00 amRNSUpdate on Commercial Pre-Launch Activities
19th Jan 20177:15 amRNSHardman Research: Infacort® - On track to market
17th Jan 20173:30 pmRNSDirector Dealings
16th Jan 20177:00 amRNSDirectors' Dealings
12th Jan 20177:00 amRNSAppointment of Chief Financial Officer
4th Jan 20173:38 pmRNSHolding(s) in Company
20th Dec 201612:08 pmRNSSubmission of Infacort® European PUMA Application
23rd Nov 201611:30 amRNSResults of Annual General Meeting
21st Nov 20167:00 amRNSFirst Patient Dosed in Testosterone Trial
9th Nov 20169:36 amRNSDirector/PDMR Shareholding
27th Oct 20167:15 amRNSHardman Research: Get the Rhythm
12th Oct 20167:00 amRNSFull Infacort Phase III Data Analysis
12th Oct 20167:00 amRNSFinal Results June 2016
12th Sep 20167:00 amRNSNotice of Results
11th Jul 20167:00 amRNSPositive headline data Infacort pivotal study
12th Apr 201612:15 pmRNSGrants of options and award of conditional shares
30th Mar 20167:00 amRNSHalf Yearly Report
22nd Mar 20163:00 pmRNSNotice of Results
29th Feb 20167:00 amRNSFirst patient dosed in Chronocort® pivotal study
19th Jan 20163:32 pmRNSHolding(s) in Company
5th Jan 20163:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.